- NeuroMab™ Anti-Tau Antibody,Clone NR2944P (Cat#: NRP-0422-P1684)
- NeuroMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- NeuroMab™ Anti-SEZ6 Antibody, Clone NR30P (Cat#: NRP-0422-P517)
- NeuroMab™ Anti-TREM2 BBB Shuttle Antibody, Clone NR19 (Cat#: NRZP-1022-ZP4114)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody,Clone NR1738P (Cat#: NRZP-1022-ZP3503)
- Tau Monoclonal Antibody (AT120, HT7 and BT2 clone) (Cat#: NK-2106-P008)
- NeuroMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody,Clone NR1707P (Cat#: NRZP-1022-ZP4050)
- NeuroMab™ Anti-Tau Antibody,Clone NR2946P (Cat#: NRP-0422-P1686)
- NeuroMab™ Anti-pTau Antibody,Clone NR3595P (Cat#: NRP-0422-P1719)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Mouse Hippocampal Neuron Cell HT22 (Cat#: NCL2110P001)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Green Fluorescent Tau SH-SY5Y cell Line (Cat#: NCL2110P219)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- C57 Brain Cortex Neurons [Mouse] (Cat#: NCC20-9PZ48)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Beta Amyloid (1-40), Aggregation Kit, TTF Assay (Cat#: NRZP-0323-ZP199)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- pAAV-syn-FLEX-jGCaMP8m-WPRE (Cat#: NTA-2106-P065)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- AAV2/9-hEF1a-DIO-mCherry-P2A-TetTox-WPRE-pA (Cat#: NTA-2012-ZP268)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-syn-FLEX-jGCaMP8f-WPRE (Cat#: NTA-2106-P064)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- ABCA1 Antisense Oligonucleotide (AK311445) (Cat#: NV-2106-P27)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein, 8D3-IL-1RA (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein, cTfRMAb-IDUA (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein, HIRMab-TNFR (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein, HIRMab-NAGLU (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein, HIRMab-GDNF (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein, cTfRMAb-TNFR (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-ASA BBB Shuttle Protein, HIRMab-ASA (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-EPO BBB Shuttle Protein, HIRMab-EPO (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein, HIRMab-IDUA (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-IDS BBB Shuttle Protein, HIRMab-IDS (Cat#: NRZP-0423-ZP503)
Neurotrophic Factors Therapies Study
In recent years, the application of trophic factors to affected areas of PD has emerged as a promising strategy. As a senior expert in the field of neuroscience, Creative Biolabs has extensive experience in Parkinson's disease (PD) mechanism of action (MoA) studies. With our advanced platform and professional scientists, Creative Biolabs is committed to providing diverse services to customers all over the world, from animal model establishment to experimental results analysis.
Introduction to Neurotrophic factors (NTFs)
NTFs are secreted proteins that play critical roles in promoting development, affecting neuronal survival and axonal growth, and regulating neuronal function. Most NTFs are members of the transforming growth factor-beta (TGF-beta) superfamily, such as glial cell line-derived neurotrophic factor (GDNF) and growth/differentiation factor (GDF). In the adult nervous system, NTFs appear to be necessary for the continued survival and phenotype maintenance of mature neurons. Furthermore, NTFs have been shown to act as anti-stimulants and antioxidants, closely associated with enhanced mitochondrial function. They are also involved in the up-regulation of calcineurin and anti-apoptotic factors. For these reasons, NTFs are regarded as an effective therapeutic strategy for the treatment of neurological diseases.
Fig.1 Major neurotrophin signaling. (Houlton, et al., 2019)
NTFs and PD
In PD, nigrostriatal dopaminergic (DA) neurons are progressively lost. With this loss below a critical level, drug therapy is less effective. Therefore, preventing cell death is a critical step in the treatment of PD. Over the past few decades, neuroprotective therapy of NTFs to relieve PD symptoms has gradually attracted widespread attention. NTFs are key regulators in the development, survival and maintenance of specific neuronal populations. Notably, these factors have the potential to slow, stop, or reverse the loss of DA neurons in PD. Studies in animal models have shown that neurotrophic factors have great potential in protecting degenerated dopamine neurons and promoting the regeneration of the nigrostriatal dopamine system.
NTFs Therapies for PD
In PD, cell death signatures involve localized regions of a single neuronal cell type, providing a discrete therapeutic target. In addition, the replacement of dopamine with exogenous levodopa is effective in PD therapy. Importantly, the available treatments do not alter the underlying disease process. For these reasons, PD is an important pioneer in NTF therapy. Most importantly, NTFs therapies offer several advantages over existing PD therapies, such as NTFs protecting remaining nigrostriatal DA neurons from further damage in addition to treating disease symptoms. In vitro research has identified a number of NTF candidates that are potent for DA neurons, with encouraging results.
Creative Biolabs specializes in providing customized services to customers around the world based on your specific needs, such as disease modeling and small molecule validation to help you gain a deeper understanding of the mechanisms of PD. Please contact us in time for more details.
Reference
- Houlton, J.; et al. Therapeutic potential of neurotrophins for repair after brain injury: a helping hand from biomaterials. Frontiers in neuroscience. 2019, 13: 790.